Orion Corporation (ORNAV.HE)

Executive Summary

Orion Corporation is a Finnish pharmaceutical company with a century-long track record in developing and commercializing therapies for CNS disorders, oncology, and respiratory diseases. The company benefits from vertical integration covering R&D, manufacturing, and marketing, and generates a significant portion of sales internationally. Its pipeline includes over 100 drug candidates, with a balanced mix of proprietary projects and partnerships, notably with Bayer on darolutamide. Orion's strong commercial portfolio, including Stalevo and Comtess for Parkinson's, provides a stable revenue base. The company is well-positioned to leverage its expertise in drug development and manufacturing. With a market cap of ~$11.3 billion, Orion remains a key player in European biotech, driven by upcoming data readouts and regulatory decisions that could expand its product portfolio and drive growth.

Upcoming Catalysts (preview)

• Q4 2026Top-line data from Phase 3 study of ODM-208 (CYP11A1 inhibitor) in metastatic castration-resistant prostate cancer70% success
• Q4 2026FDA decision on supplemental New Drug Application for darolutamide in a new prostate cancer indication (e.g., metastatic hormone-sensitive prostate cancer label expansion)80% success
• Q3 2026Initiation of Phase 2 trial for ODM-203 (dual FGFR/VEGFR inhibitor) in solid tumors60% success